MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil (CMF)

Ann Oncol. 2000 Mar;11(3):373-4. doi: 10.1023/a:1008337900349.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / genetics
  • Cyclophosphamide / adverse effects
  • Female
  • Fluorouracil / adverse effects
  • Humans
  • Methotrexate / adverse effects
  • Methylenetetrahydrofolate Reductase (NADPH2)
  • Middle Aged
  • Oxidoreductases Acting on CH-NH Group Donors / genetics*
  • Polymorphism, Genetic

Substances

  • Cyclophosphamide
  • Oxidoreductases Acting on CH-NH Group Donors
  • Methylenetetrahydrofolate Reductase (NADPH2)
  • Fluorouracil
  • Methotrexate